Fecha de la publicación: 01/10/2019
Autor: Estefanía Cantador (1), Alberto Núñez (2), Pilar Sobrino (1), Victoria Espejo (2), Lucía Fabia (1), Lydia Vela (1), Luis de Benito (3), Javier Botas (4, 5)
1Neurology Department, Hospital Universitario Fundación Alcorcón, Calle Budapest, 1., 28922, Madrid, Spain.
2Cardiology Department, Hospital Universitario Fundación Alcorcón, Calle Budapest, 1., 28922, Madrid, Spain.
3Department of Vascular Surgery, Hospital Universitario Fundación Alcorcón, Calle Budapest, 1., 28922, Madrid, Spain.
4Cardiology Department, Hospital Universitario Fundación Alcorcón, Calle Budapest, 1., 28922, Madrid, Spain. email@example.com.
5Rey Juan Carlos University School of Medicine, Madrid, Spain. firstname.lastname@example.org.
A high incidence of thrombotic events, particularly deep vein thrombosis and pulmonary embolism, has been clearly documented in COVID-19 patients. In addition, small series of patients with coronary, cerebrovascular and peripheral arterial thrombotic events have also been reported, but their true incidence and consequences are not well described, and constitute the objective of this study. From February 1st to April 21st, 2020, 2115 COVID-19 patients were treated at Hospital Universitario Fundación Alcorcón (Madrid, Spain), and 1419 were eventually admitted. Patient characteristics and outcomes were collected by reviewing their electronic medical records. Fourteen patients had a systemic arterial thrombotic event, which represents a 1% incidence in relation to the total number of hospitalized patients. Three patients suffered an acute coronary syndrome, two with persistent ST-segment elevation, one of whom was treated invasively, and one with transient ST-segment elevation. Eight patients had a cerebrovascular event. Six suffered an acute ischemic stroke and two a transient ischemic attack, 50% of them had a Rankin score ≥ 3 at discharge. Three additional patients had a limb thrombotic event, all of them infrapopliteal, and were managed conservatively. All three cases developed necrosis of the toes, two of them with bilateral involvement. The hospitalization death rate of patients with an arterial event was 28.6%. Although COVID-19 may favor the occurrence of thrombotic events, the destabilization and thrombosis of arterial atherosclerotic plaques do not seem to be a frequent mechanism which warrants the need for specific systematic preventive measures.